Study the Effect Hypericum perforatum medicine on spinal cord injury

Investigating the Effect of Hypericum perforatum (Perforan) Tablets on Neurological Pain, Functional Independence and Severity of Depression in Patients with Spinal Cord Injuries

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241118063767N1

Enrollment

Registered

2024-12-04

Start date

2025-01-19

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury. Injury of spinal cord, level unspecified

Interventions

Intervention 1: Intervention group: Perforan tablets (Hypericum perforatum), Gol Daru Company. It has a license from the Food and Drug Administration, one tablet 3 times a day. Intervention 2: Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Full consent to participate in the study At least one month has passed from the lesion and the patient is in the sub-acute phase

Exclusion criteria

Exclusion criteria: Acute and chronic phases of spinal cord injury Intolerance, allergic reaction or unexpected laboratory changes identified by the patient or specialist physician Medications that may interact with Perforan tablets (Such as cytochrome P450 inducers, SSRI and MAOI drugs, blood pressure lowering drugs, anticoagulant drugs)

Design outcomes

Primary

Measure	Time frame
Neurological Pain. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Numeric Rating Scale.;Functional Independence. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Functional Independence Measure (FIM) Questionnaire.;Depression severity. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Beck Depression Inventory.;Spinal Cord Independence Measure. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Spinal Cord Independence Measure (SCIM) Questionnaire.	—

Measure

Time frame

Neurological Pain. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Numeric Rating Scale.;Functional Independence. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Functional Independence Measure (FIM) Questionnaire.;Depression severity. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Beck Depression Inventory.;Spinal Cord Independence Measure. Timepoint: Before the start of the intervention and 21 days after the start of treatment. Method of measurement: Spinal Cord Independence Measure (SCIM) Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansooreh Sadat Mojani Qomi

Islamic Azad University

mansooreh.moujani@gmail.com+98 21 2264 0052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026